Navigation Links
INNOPHARMA Receives First FDA Approval
Date:2/2/2010

MONMOUTH JUNCTION, N.J., Feb. 2 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of the Abbreviated New Drug Application (ANDA) for ibutilide fumarate injection (the generic equivalent of Corvert® from Pfizer Inc).

As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with Bioniche Pharma USA for marketing and product distribution of the injection product. Ibutilide fumarate injection represents INNOPHARMA's first approved drug in their product pipeline.

Please refer to the Bioniche Pharma website to be directed to the complete prescribing information for this product, including the boxed warning.

About INNOPHARMA:

INNOPHARMA is a research and development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of parenteral pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.  

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com.

SOURCE INNOPHARMA LLC

RELATED LINKS
http://www.innopharmallc.com

'/>"/>

SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Mylan Receives Approval for Generic Version of GoLytely(R)
3. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
4. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
5. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
6. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
7. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
8. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
10. GeneGo Receives SBIR Grant
11. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition ... - 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics ... the growing market of deep learning solutions within the healthcare domain. ... emerged as a novel solution to generate relevant insights from medical ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... March 23, 2017  Mirabilis Medical, a ... technology for non-invasive surgery, announced today CE Mark ... treatment of uterine fibroids throughout the European Union.  ... approval from the US Food and Drug Administration ... System in the United States.  The Mirabilis System ...
Breaking Medicine Technology:
(Date:3/25/2017)... Kennett Square, PA (PRWEB) , ... March 25, 2017 , ... ... one priority as a public relations partner. , All through the year, Garden ... stories and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... , ... According to a new study by NCPA Senior Fellow John R. ... rules Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare ... it estimates a reduction in employer-based coverage due to the GOP reform, which is ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
Breaking Medicine News(10 mins):